- Home
- UL vs VRTX Comparison
UL vs VRTX Comparison
Compare UL & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- VRTX
- Stock Information
- Founded
- UL 1930
- VRTX 1989
- Country
- UL United Kingdom
- VRTX United States
- Employees
- UL N/A
- VRTX N/A
- Industry
- UL Package Goods/Cosmetics
- VRTX EDP Services
- Sector
- UL Consumer Discretionary
- VRTX Technology
- Exchange
- UL Nasdaq
- VRTX Nasdaq
- Market Cap
- UL 143.0B
- VRTX 128.5B
- IPO Year
- UL N/A
- VRTX 1991
- Fundamental
- Price
- UL $57.91
- VRTX $467.01
- Analyst Decision
- UL Buy
- VRTX Buy
- Analyst Count
- UL 4
- VRTX 29
- Target Price
- UL $60.00
- VRTX $513.58
- AVG Volume (30 Days)
- UL 2.1M
- VRTX 1.2M
- Earning Date
- UL 07-25-2024
- VRTX 11-04-2024
- Dividend Yield
- UL 3.28%
- VRTX N/A
- EPS Growth
- UL N/A
- VRTX N/A
- EPS
- UL 2.82
- VRTX N/A
- Revenue
- UL $64,601,950,064.00
- VRTX $10,625,800,000.00
- Revenue This Year
- UL $2.95
- VRTX $12.20
- Revenue Next Year
- UL $3.20
- VRTX $8.31
- P/E Ratio
- UL $19.97
- VRTX N/A
- Revenue Growth
- UL N/A
- VRTX 10.06
- 52 Week Low
- UL $46.46
- VRTX $346.29
- 52 Week High
- UL $65.87
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- UL 32.02
- VRTX 42.88
- Support Level
- UL $56.87
- VRTX $489.02
- Resistance Level
- UL $57.65
- VRTX $519.88
- Average True Range (ATR)
- UL 0.52
- VRTX 14.86
- MACD
- UL -0.25
- VRTX -2.67
- Stochastic Oscillator
- UL 20.68
- VRTX 14.49
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.